stockrowKoninklijke Philips N.V.
PHG Healthcare Medical Devices
Koninklijke Philips N.V.’s revenue for fiscal 2025 (year ended December 2025) was $20.2 billion, up 3.47% from fiscal 2024.
- Revenue
- +0.55%
- EPS
- −85.0%
- Free cash flow
- +154.2%
- Total debt
- −4.96%
Quarter to September 2026, against a year earlier
Follow PHG
Alert me
Koninklijke Philips N.V. (PHG) EPS (diluted)
Koninklijke Philips N.V.'s EPS (diluted) for fiscal 2025 was $1.05, compared with −$0.81 in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.17. Over the past ten years it has ranged from −$1.92 (fiscal 2022) to $4.32 (fiscal 2021); the current reading is higher than 45% of that period. Koninklijke Philips N.V. ranks 25th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.05 | — |
| FY2024 | −$0.81 | — |
| FY2023 | −$0.55 | — |
| FY2022 | −$1.92 | — |
| FY2021 | $4.32 | 193.88% |
| FY2020 | $1.47 | 2.80% |
| FY2019 | $1.43 | 4.38% |
| FY2018 | $1.37 | (30.81%) |
| FY2017 | $1.98 | 14.45% |
| FY2016 | $1.73 | 121.79% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.03 | (93.06%) |
| Jun 2026 | $0.47 | 151.34% |
| Mar 2026 | $0.19 | (61.04%) |
| Dec 2025 | $0.48 | 118.18% |
| 37 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| STE STERIS plc compare | $8.43 |
| GEHC GE HealthCare Technologies Inc. compare | $4.76 |
| ZBH Zimmer Biomet Holdings, Inc. compare | $3.96 |
| DXCM DexCom, Inc. compare | $2.55 |
| BSX Boston Scientific Corporation compare | $2.36 |
| EW Edwards Lifesciences Corporation compare | $1.77 |
| PHG Koninklijke Philips N.V. | $1.17 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PHG
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement